empirical therapy-National Taiwan University Hospital-Helicobacter pylori infection

Empirical therapy-National Taiwan University Hospital-Helicobacter pylori infection refers to a specific multi-drug treatment regimen evaluated in clinical trials (notably NCT02124005) for the third-line eradication of *Helicobacter pylori*. This regimen is a combination therapy consisting of the proton pump inhibitor esomeprazole (Nexium) and a sequential antibiotic protocol. Patients receive esomeprazole for 14 days, combined with amoxicillin and metronidazole (Flagyl) for the first 7 days. During the second week (days 8-14), a third antibiotic—either levofloxacin (Cravit), clarithromycin (Klaricid), or tetracycline—is added based on the patient's prior medication history. The regimen is designed to overcome antibiotic resistance in refractory *H. pylori* cases by utilizing a high-dose PPI to stabilize antibiotics and a rotating combination of antimicrobial agents with distinct mechanisms of action, including cell wall synthesis inhibition, DNA damage, and protein synthesis inhibition.

Brand names

NexiumFlagylCravitKlaricid

Other names

esomeprazole + amoxicillin + metronidazole + levofloxacin + clarithromycin + tetracyclineempirical third-line therapy (NTUH)empirical therapy (NTUH)